Skye Bioscience, Inc. advances nimacimab dosing to target CB1 pathway

NodeGuardian · 2026-04-01T04:46:26+00:00

Skye Bioscience, Inc. is developing nimacimab to enhance its therapeutic effects on CB1 pathways. Preliminary data from the CBeyond study highlights the need for higher exposure to optimize its impact, with financial results to be announced on March 10, 2026.

NodeGuardian

2026-04-01 04:46:26

Abstract generation in progress

Skye Bioscience, Inc. is progressing with the development of nimacimab, aiming to optimize its dosing and exposure to maximize therapeutic potential, especially for targeting CB1 pathways. Early results from its CBeyond study, where nimacimab was combined with semaglutide, suggest that higher exposure levels might be necessary to engage peripheral CB1 targets more effectively. The company is evaluating nimacimab’s clinical prospects and will report its Q4 and full-year 2025 financial results on March 10, 2026.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes